FDA Approves Biosimilar Ustekinumab-aekn for PsO, PsA
The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Full Papers; Authors: X. Li, C. Ma, J. Xu, M. Zhang, Q. Xiang, Y. Li, W. Li, P. Zhu
An analysis of NHANES found aspirin’s benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.
At least 3 of 4 athletes will not only return to sport after hip arthroscopy but also maintain durability in their sport regardless of high-impact…
An analysis of NHANES found aspirin’s benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.
There is a positive association between maternal autoimmune disease and childhood cancer. This association is especially prominent in the offspring of women with rheumatoid arthritis.
The deep impact of mild plaque psoriasis
The 6th Annual Global Spondyloarthritis (SpA) Summit, hosted by the Spondylitis Association of America (SAA), will be held virtually on May 3-4, 2024. Under the…
Musculoskeletal consultations constitute a growing portion of primary care physician (PCP) referrals. Optimizing communication between PCPs and orthopaedists can potentially reduce time spent in the…
Nature Reviews Rheumatology – Granzyme serine proteases are known for their perforin-dependent cytotoxic activities, but evidence also indicates that they have a range of non-cytotoxic,…
Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed…